Literature DB >> 9241467

Visual electrophysiology in Parkinson's disease: PERG, VEP and visual P300.

I Bodis-Wollner1.   

Abstract

A retinal dopaminergic deficiency underlies some visual changes in Parkinson's disease (PD), in particular those elicited by stimuli near the peak of the human and monkey spatial contrast sensitivity. The correspondence of retinal changes and VEP alterations is not perfect: they do not seem to rely on identical mechanisms. It seems that additional pathology beyond the retina affects visual responses, including VEPs. The relevance of "distal" primary VEP changes to higher cognitive visual abnormalities in PD is not established at present.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9241467     DOI： 10.1177/155005949702800305

Source DB:  PubMed          Journal:  Clin Electroencephalogr        ISSN： 0009-9155


  12 in total

1.  Absence of DJ-1 causes age-related retinal abnormalities in association with increased oxidative stress.

Authors:  Vera L Bonilha; Brent A Bell; Mary E Rayborn; Ivy S Samuels; Anna King; Joe G Hollyfield; Chengsong Xie; Huaibin Cai
Journal:  Free Radic Biol Med       Date:  2017-01-11       Impact factor: 7.376

Review 2.  Inner blood-retinal barrier transporters: role of retinal drug delivery.

Authors:  Ken-ichi Hosoya; Masanori Tachikawa
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

3.  The effect of docosahexaenoic Acid on visual evoked potentials in a mouse model of Parkinson's disease: the role of cyclooxygenase-2 and nuclear factor kappa-B.

Authors:  Ozlem Ozsoy; Gamze Tanriover; Narin Derin; Nimet Uysal; Necdet Demir; Burcu Gemici; Ceren Kencebay; Piraye Yargicoglu; Aysel Agar; Mutay Aslan
Journal:  Neurotox Res       Date:  2011-01-14       Impact factor: 3.911

4.  Lipophilicity and transporter influence on blood-retinal barrier permeability: a comparison with blood-brain barrier permeability.

Authors:  Ken-ichi Hosoya; Atsushi Yamamoto; Shin-ichi Akanuma; Masanori Tachikawa
Journal:  Pharm Res       Date:  2010-09-22       Impact factor: 4.200

Review 5.  Treatment of Visual Disorders in Parkinson Disease.

Authors:  Joseph Savitt; Michaela Mathews
Journal:  Curr Treat Options Neurol       Date:  2018-06-23       Impact factor: 3.598

6.  Reduced macular thickness and macular vessel density in early-treated adult patients with PKU.

Authors:  Csilla Serfozo; Andras Gellert Barta; Endre Horvath; Csaba Sumanszki; Bela Csakany; Miklos Resch; Zoltan Zsolt Nagy; Peter Reismann
Journal:  Mol Genet Metab Rep       Date:  2021-05-05

7.  Biology of Parkinson's disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder.

Authors:  Garrett E Alexander
Journal:  Dialogues Clin Neurosci       Date:  2004-09       Impact factor: 5.986

8.  Can Variability of Pattern ERG Signal Help to Detect Retinal Ganglion Cells Dysfunction in Glaucomatous Eyes?

Authors:  Alberto Mavilio; Francesca Scrimieri; Donato Errico
Journal:  Biomed Res Int       Date:  2015-06-08       Impact factor: 3.411

9.  RE-PERG, a new procedure for electrophysiologic diagnosis of glaucoma that may improve PERG specificity.

Authors:  Alberto Mavilio; Dario Sisto; Paolo Ferreri; Nicola Cardascia; Giovanni Alessio
Journal:  Clin Ophthalmol       Date:  2017-01-23

10.  Effect of optical flow versus attentional strategy on gait in Parkinson's Disease: a study with a portable optical stimulating device.

Authors:  Maurizio Ferrarin; Marco Rabuffetti; Mauro Tettamanti; Riccardo Pignatti; Alessandro Mauro; Giovanni Albani
Journal:  J Neuroeng Rehabil       Date:  2008-01-18       Impact factor: 4.262
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.